# Perlegen Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/perlegen-sciences

- Industry: Biotechnology
- Headquarters: Mountain View, US
- Total disclosed funding: $104M
- Latest round: Series D (Feb 1, 2005)
- Investors on record: 16

## About

Perlegen Sciences, Inc. provide physicians with information to improve the clinical decision-making process and patient treatment outcomes.

## Funding rounds

- Series D, Feb 1, 2005, $74M — Zesiger Capital Group, Unilever Ventures, Presidio Partners, Brookside Capital Partners, Whiz Partners, Mizuho Securities, Biofrontier Partners, SB Life Science, MPM BioImpact, British Standards Institution (BSI), Glynn Capital, Maverick Capital, Cape Securities
- Series C, Jan 27, 2003, $30M — Unilever Ventures, Presidio Partners, Whiz Partners, Biofrontier Partners, SB Life Science, Vulcan, Maverick Capital, Biomedical Sciences Investment Fund, Eli Lilly & Company

## Investors

- Unilever Ventures (https://capitalatlas.ai/funds/unilever-ventures) — Series C, Series D
- Presidio Partners (https://capitalatlas.ai/funds/presidio-partners) — Series C, Series D
- Whiz Partners (https://capitalatlas.ai/funds/whiz-partners) — Series C, Series D
- Biofrontier Partners (https://capitalatlas.ai/funds/biofrontier-partners) — Series C, Series D
- SB Life Science (https://capitalatlas.ai/funds/sb-life-science) — Series C, Series D
- Vulcan (https://capitalatlas.ai/funds/vulcan) — Series C
- Maverick Capital (https://capitalatlas.ai/funds/maverick-capital) — Series C, Series D
- Biomedical Sciences Investment Fund — Series C
- Eli Lilly & Company — Series C
- Zesiger Capital Group (https://capitalatlas.ai/funds/zesiger-capital-group) — Series D
- Brookside Capital Partners (https://capitalatlas.ai/funds/brookside-capital-partners) — Series D
- Mizuho Securities — Series D
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series D
- British Standards Institution (BSI) — Series D
- Glynn Capital (https://capitalatlas.ai/funds/glynn-capital) — Series D
- Cape Securities — Series D